Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

6420 LEVIT GREEN BOULEVARD, SUITE 210, Houston, United States

ajmrtxl Jul. 3 at 4:19 PM

$PSTV 's latest squeeze play

0 · Reply

Longintactandinminent Jul. 3 at 3:32 PM

$PSTV game over old world.

0 · Reply

MrWicks Jul. 3 at 1:08 AM

$PSTV .. Easter Monday 3.84 high tap today. This one owes me some money eventually.

0 · Reply

Longintactandinminent Jul. 2 at 6:51 PM

$PSTV if closenbelow 4 game over. 4-20 gone them back to 2.75 2.45 1.75 1.44 0.78 0.72 0.49 and so on

0 · Reply

Longintactandinminent Jul. 2 at 6:50 PM

$PSTV dilution very clear.

0 · Reply

nobodyyk Jul. 2 at 5:31 PM

$PSTV

0 · Reply

Longintactandinminent Jul. 2 at 5:30 PM

$PSTV lmao

0 · Reply

andre82 Jul. 2 at 4:45 PM

$PSTV Enjoy the upcoming losses bulls - you have been warned an infinite amount of times. Short with us or get out of the way! Starting the holiday weekend early here - HAPPY HOLIDAYS for the US users.

1 · Reply

andre82 Jul. 2 at 3:37 PM

$PSTV Uh oh - here comes the ATM truck full of shares! 🤣

0 · Reply

MisterSuper Jul. 2 at 3:15 PM

$PSTV picked up another 500 - why not? Possible inflection point

1 · Reply

Plus Therapeutics Transcript: Investor update

Jun 30, 2026, 8:30 AM EDT - 4 days ago

Plus Therapeutics Press release: Investor update

2026-06-30T11:45:09.000Z - 4 days ago

Plus Therapeutics to change name, ticker symbol

Jun 30, 2026, 7:30 AM EDT - 4 days ago

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Jun 25, 2026, 7:30 AM EDT - 9 days ago

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Jun 23, 2026, 7:30 AM EDT - 11 days ago

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Jun 5, 2026, 8:00 AM EDT - 4 weeks ago

Plus Therapeutics Registration statement: Registration filing

Jun 4, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

Plus Therapeutics Registration statement: Registration filing

2026-06-02T10:13:30.000Z - 4 weeks ago

Plus Therapeutics files $100M mixed securities shelf

2026-05-26T13:10:52.000Z - 5 weeks ago

Plus announces presentation of health economics study on CNSide CSF assay

May 26, 2026, 7:30 AM EDT - 5 weeks ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

2026-05-19T11:35:32.000Z - 6 weeks ago

Plus Therapeutics enters pact with Ephemeral for AI execution platform

May 19, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

2026-05-15T20:11:34.000Z - 7 weeks ago

Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)

May 15, 2026, 4:05 PM EDT - 7 weeks ago

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 15, 2026, 4:00 PM EDT - 7 weeks ago

Plus Therapeutics Earnings release: Q1 2026

May 15, 2026, 4:00 PM EDT - 7 weeks ago

Plus Therapeutics Quarterly report: Q1 2026

May 14, 2026, 9:00 AM EDT - 7 weeks ago

Plus Therapeutics Transcript: AGM 2026

May 8, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 8, 2026, 7:00 AM EDT - 2 months ago

Plus Therapeutics Slides: FY 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 2 months ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T11:59:57.000Z - 2 months ago

Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement

Apr 21, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

2026-04-09T11:57:58.000Z - 3 months ago

Plus Therapeutics appoints Eric Daniels as chief development officer

Apr 9, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

2026-04-08T11:39:50.000Z - 3 months ago

Plus Therapeutics granted Orphan Drug Designation for Reyobiq

Apr 8, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

2026-04-07T15:15:27.000Z - 3 months ago

Plus Therapeutics price target lowered to $12 from $37.50 at Maxim

2026-04-07T11:55:34.000Z - 3 months ago

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Apr 7, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

2026-04-06T22:20:10.000Z - 3 months ago

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

Apr 2, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

2026-04-01T23:50:16.000Z - 3 months ago

Plus Therapeutics Inc (USA) trading halted, news pending

2026-03-31T14:45:55.000Z - 3 months ago

Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Plus Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Plus Therapeutics Proxy statement: Proxy filing

2026-03-31T11:38:10.000Z - 3 months ago

Plus Therapeutics announces 1-for-25 reverse stock split

Mar 26, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

2026-03-19T12:01:47.000Z - 3 months ago

Plus Therapeutics’ CNSide assay may reduce healthcare costs

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

2026-03-12T21:05:16.000Z - 4 months ago

Plus Therapeutics reports Q4 EPS (29c), consensus (4c)

Mar 12, 2026, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Plus Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Plus Therapeutics Annual report: Q4 2025

2026-02-25T12:39:49.000Z - 4 months ago

Plus announces new Category III CPT code for CED used with Reyobiq

Feb 25, 2026, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

2026-02-03T13:40:32.000Z - 5 months ago

Plus Therapeutics initiated with a Buy at Lake Street

2026-01-23T15:00:32.000Z - 5 months ago

Plus Therapeutics price target lowered to $1.50 from $3 at Maxim

2026-01-23T11:11:22.000Z - 5 months ago

Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Transcript: Business update

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Press release: Business update

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Slides: Business update

Jan 21, 2026, 4:15 PM EST - 5 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 8:00 AM EST - 6 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 9, 2026, 7:00 AM EST - 6 months ago

Plus Therapeutics Registration statement: Registration Filing

Jan 8, 2026, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 5:00 PM EDT - 8 months ago

Plus Therapeutics Quarterly report: Q3 2025

Oct 30, 2025, 5:00 PM EDT - 8 months ago

Plus Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 4:15 PM EDT - 8 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 11 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Plus Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Plus Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Registration statement: Registration Filing

Aug 1, 2025, 8:00 AM EDT - 1 year ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 10, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

ajmrtxl Jul. 3 at 4:19 PM

$PSTV 's latest squeeze play

0 · Reply

Longintactandinminent Jul. 3 at 3:32 PM

$PSTV game over old world.

0 · Reply

MrWicks Jul. 3 at 1:08 AM

$PSTV .. Easter Monday 3.84 high tap today. This one owes me some money eventually.

0 · Reply

Longintactandinminent Jul. 2 at 6:51 PM

$PSTV if closenbelow 4 game over. 4-20 gone them back to 2.75 2.45 1.75 1.44 0.78 0.72 0.49 and so on

0 · Reply

Longintactandinminent Jul. 2 at 6:50 PM

$PSTV dilution very clear.

0 · Reply

nobodyyk Jul. 2 at 5:31 PM

$PSTV

0 · Reply

Longintactandinminent Jul. 2 at 5:30 PM

$PSTV lmao

0 · Reply

andre82 Jul. 2 at 4:45 PM

1 · Reply

andre82 Jul. 2 at 3:37 PM

$PSTV Uh oh - here comes the ATM truck full of shares! 🤣

0 · Reply

MisterSuper Jul. 2 at 3:15 PM

$PSTV picked up another 500 - why not? Possible inflection point

1 · Reply

Longintactandinminent Jul. 2 at 2:11 PM

$PSTV good news bulls. Tomorrow no market.

1 · Reply

andre82 Jul. 2 at 1:30 PM

$PSTV sub 4 coming in hot 🔥. Sub 3 before end of July if we are lucky.

0 · Reply

RemitTekram Jul. 2 at 12:38 PM

$RFL $SLS $PSTV

2 · Reply

Longintactandinminent Jul. 2 at 7:55 AM

$PSTV @plustherapeutics great strategy

0 · Reply

Marketmoverjoe Jul. 1 at 9:09 PM

$PSTV love how they are talking about rebranding. Give me a break. stop robbing your shareholders with your lies and fluff bs. You've been given enough money to go to the moon and back.

0 · Reply

andre82 Jul. 1 at 8:21 PM

$PSTV Bulls are toast until the offering is closed (estimate late q4, but may drag into 2027).

1 · Reply

Longintactandinminent Jul. 1 at 5:38 PM

$PSTV bears prevalente because company IS scamming people for years, reverse split, dilution, high salaries,

0 · Reply

Master_Han Jul. 1 at 4:09 PM

$PSTV Why bears are prevalent here? The company has been through the worst. They are on track with hitting their CNSIDE targets. Their aggressive moves earlier this year gives them enough cash till the better part of next year. On top of that they have revenues from CNSIDE tests, so if they needed cash in the first or second quarter of 2027, it wouldn’t be like 2026. Probably issue some shares in the market like every other company does. Bears are going to run for their money very soon causing short squeeze in the market. The likes of which we saw with GameStop at one point. A lot of people are in negative value right now due to the negative sentiment spread in the market, but they forget that there is only so much Bears can manipulate. Beyond Bears’ fear spreading tactics, they don’t have any concrete points. Like you see some people here, they are either igniting anger in people or causing fear, nothing educational in their comments. They only come out when people are in doubts.

2 · Reply

andre82 Jul. 1 at 1:45 PM

$PSTV Congrats on all the big news. Now lets turn on the ATM dilution machine and run it until the offering is needed please

0 · Reply

Longintactandinminent Jul. 1 at 1:34 PM

$PSTV P.O.S.T.V

0 · Reply

plustherapeutics Jul. 1 at 1:12 PM

Along with the excitement around the $PSTV rebrand to Cerenome and ticker change CNSY, our latest press release included several more key updates: - Year-to-date, 232 CNSide tumor cell enumeration tests have been performed, and are on track to achieve a run rate of 1,250 tests per annum by the end of 2026 - June was the highest volume month on record, with 72 CNSide Diagnostics' tests performed - Based on the growth in test requisitions, Plus expects to achieve a run rate of 1,250 tests per annum by the end of 2026 - 18 institutions are onboarded and ordering - 17 additional institutions are in process and approximately 70 individual end-user portal agreements have been signed by healthcare providers and their staffs Check out the full press release to stay updated on the company’s latest key milestones and positive commercial progress: https://bit.ly/4vz4OPn

4 · Reply

Longintactandinminent Jul. 1 at 10:52 AM

$PSTV I think now, looking back, we did not fight the enemy; we fought ourselves. And the enemy was in us. The war is over for me now, but it will always be there, the rest of my days

0 · Reply

Market Cap	27.40M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.06

Volume	223,200
Avg Vol	185,084
Day's Range	N/A - N/A
Shares Out	6.88M
Stochastic %K	21%
Beta	1.40
Analysts	Sell
Price Target	$34.50